fda bpc-157 warning bpc-157 not approved for human use fda warning The Hidden Risks of BPC‑157: What Patients Need to Know About Contamination and Safety bpc-157 regulation fda fda bpc-157

Researchers observe a marked increase in metabolic expenditure and mitochondrial biogenesis within treated isolated cell cultures

no Phase II or III trials published Most common AOD-9604 side effect / Injection-site reaction (redness, swelling) Most common reported MOTS-c side effect / Transient flushing and mild GI discomfort (anecdotal, not trial-confirmed) Growth hormone axis impact / AOD-9604 does not activate the GH receptor

The absence of a matching report should not be interpreted as independent verification

Because cagrilintide is typically used at very low concentrations in assay systems, solubility at the working concentration is rarely a limiting factor even without special solvents

Whyte, T